Dupont Capital Management’s Pacira BioSciences PCRX Stock Holding History

Dupont Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25,664	Closed	-$1.16M	–	1356
2019 Q4	$1.16M	Hold	25,664	–	–	0.03%	528
2019 Q3	$977K	Buy	+25,664	New	+$1.02M	0.02%	532
2017 Q4	–	Sell	-15,090	Closed	-$567K	–	981
2017 Q3	$567K	Buy	15,090 +1,821	+14%	+$73.3K	0.01%	647
2017 Q2	$633K	Sell	13,269 -5,192	-28%	-$241K	0.01%	628
2017 Q1	$842K	Sell	18,461 -5,087	-22%	-$220K	0.02%	558
2016 Q4	$761K	Buy	23,548 +17,791	+309%	+$594K	0.02%	553
2016 Q3	$197K	Hold	5,757	–	–	﹤0.01%	641
2016 Q2	$194K	Hold	5,757	–	–	﹤0.01%	648
2016 Q1	$305K	Sell	5,757 -7,232	-56%	-$423K	0.01%	593
2015 Q4	$997K	Buy	+12,989	New	+$735K	0.02%	472

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Dupont Capital Management's PCRX Position: Q1 2020 in Review

Dupont Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 25,664 shares — an estimated $1.16M sold.

Dupont Capital Management first reported a position in PCRX in Q4 2015 and held it in 10 quarters. The position peaked at $1.16M in Q4 2019. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

Dupont Capital Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
Dupont Capital Management sold 25,664 Pacira BioSciences shares in Q1 2020, an estimated $1.16M.
Dupont Capital Management first reported a position in Pacira BioSciences in Q4 2015 and held it in 10 quarters.
Dupont Capital Management's Pacira BioSciences position peaked at $1.16M in Q4 2019.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Dupont Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.